ANI Pharmaceuticals (ANIP) Advances While Market Declines: Some Information for Investors

Group 1 - ANI Pharmaceuticals (ANIP) closed at $57.03, reflecting a +0.92% change from the previous day's close, outperforming the S&P 500's daily loss of 0.1% [1] - Over the past month, ANI Pharmaceuticals' shares have decreased by 0.41%, underperforming the Medical sector's gain of 2.32% and the S&P 500's gain of 5.78% [1] - The upcoming earnings report is scheduled for February 29, 2024, with projected EPS of $0.78, indicating a 2.63% increase year-over-year, and revenue expected to be $119.38 million, a 26.69% increase year-over-year [1] Group 2 - Recent changes to analyst estimates for ANI Pharmaceuticals reflect short-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [2] - The Zacks Rank system, which assesses estimate changes, currently ranks ANI Pharmaceuticals at 3 (Hold), with the consensus EPS estimate remaining stagnant over the past month [2] - Stocks rated 1 in the Zacks Rank have historically produced an average annual return of +25% since 1988 [2] Group 3 - ANI Pharmaceuticals has a Forward P/E ratio of 13.92, which is a discount compared to the industry's average Forward P/E of 21.34 [3] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 97, placing it in the top 39% of over 250 industries [3] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [3]